Nirsevimab: The Hidden Costs

被引：4
|
作者：
Neumann, Samantha [1 ,2 ]
Alverson, Brian [1 ,2 ]
机构：
[1] Nemours Childrens Hlth, Wilmington, DE USA
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
来源：
HOSPITAL PEDIATRICS | 2024年 / 14卷 / 06期
关键词：
RESPIRATORY SYNCYTIAL VIRUS; INFANTS; RSV;
D O I：
10.1542/hpeds.2024-007739
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
[No abstract available]
引用
收藏
页码：e276 / e278
页数：3
相关论文
共 50 条
  • [31] Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes
    Kieffer, Alexia
    Beuvelet, Matthieu
    Moncayo, Gerald
    Chetty, Mersha
    Sardesai, Aditya
    Musci, Robert
    Hudson, Richard
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (10) : 2135 - 2153
  • [32] Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024
    Wadia, Ushma
    Moore, Hannah C.
    Richmond, Peter C.
    Levy, Avram
    Bell, Lana
    Pienaar, Catherine
    Harvey, Joanne
    Finucane, Caroline
    van der Helder, Erin
    Bloomfield, Lauren
    Cheng, Allen
    Effler, Paul
    Blyth, Christopher C.
    JOURNAL OF INFECTION, 2025, 90 (04)
  • [33] Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study
    Jeziorski, Eric
    Ouziel, Antoine
    Cotillon, Marie
    Bridonneau, Constance
    Bizot, Etienne
    Basse, Clement
    Portefaix, Aurelie
    Dubos, Francois
    Bechet, Stephane
    Domitien, Lea
    Jaillet, Carine
    Abrudan, Sorin
    Kramer, Rolf
    Gajdos, Vincent
    Launay, Elise
    Basmaci, Romain
    Gillet, Yves
    Cohen, Robert
    Levy, Corinne
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2025, 44 (04) : e124 - e126
  • [34] Nirsevimab for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and Infants
    不详
    AUSTRALIAN PRESCRIBER, 2024, 47 (03) : 102 - 103
  • [35] Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
    Marcellusi, Andrea
    Bini, Chiara
    Muzii, Barbara
    Soudani, Samira
    Kieffer, Alexia
    Beuvelet, Matthieu
    Bozzola, Elena
    Midulla, Fabio
    Baraldi, Eugenio
    Bonanni, Paolo
    Boccalini, Sara
    Orfeo, Luigi
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2025, 12 : 16 - 28
  • [36] Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use
    Shirley, Matt
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (12) : 413 - 420
  • [37] Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?
    Homaira, Nusrat
    TRANSLATIONAL PEDIATRICS, 2024, 13 (03) : 525 - 529
  • [38] Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia
    Buendia, Jefferson Antonio
    Acuna-Cordero, Ranniery
    Rodriguez-Martinez, Carlos E.
    PEDIATRIC PULMONOLOGY, 2024, 59 (05) : 1372 - 1379
  • [39] CDC changes recommendations due to severe nirsevimab shortage during the 2023-2024 RSV season
    Rahmat, Zainab Syyeda
    Ahmad, Shkaib
    Malikzai, Abdullah
    PEDIATRIC PULMONOLOGY, 2024, 59 (04) : 1108 - 1109
  • [40] The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
    Turalde-Mapili, Maria Wilma R.
    Mapili, Jerahmeel Aleson L.
    Turalde, Christian Wilson R.
    Pagcatipunan, Marimel R.
    FRONTIERS IN PEDIATRICS, 2023, 11
12345